NPM1 and acute myeloid leukemia: NPM1 mutations in AML define a distinct leukemia entity [WHO classification 2022 and ICC 2022: AML-defining recurrent genetic abnormalities], can act as founder mutations that are stable over the course of disease (3–6), and are not expressed in normal tissue (7).